High Throughput Screening Market Size, Share, Growth, Trends, and Global Industry Analysis: By Products & Services (Consumables (Reagents & Assay Kits & Laboratory Equipment), By Instruments (Liquid Handling Systems, Detection Systems, Others), Services, and Software), By Technology (Cell-based Assays, (Fluorometric Imaging Plate Reader Assays, Reporter based Assays, 3D - Cell Cultures, 2D - Cell Cultures, Reporter-based Assays, and Perfusion Cell Culture), Lab-on-a-chip Technology (LOC), Label-free Technology, and Ultra-High Throughput Screening), By Application (Drug Discovery Programs, Chemical Biology Programs, Biochemical Screening, and Cell & Organ-based Screening),  By End Use (Pharmaceutical & Biopharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations (CROs), and Others), and Region Forecast 2019-2030

High throughput screening market size was valued at US$ 23,732.7 million in 2023 and is projected to grow at a CAGR of 9.2% from 2024-2030. The pharmaceutical and biotechnology industries' increasing need for rapid and efficient drug discovery processes is fueling the high-throughput screening (HTS) market. The need for tailored therapy and the increase in chronic illnesses have made HTS technology more important. Furthermore, screening procedures are becoming more accurate and efficient due to developments in automation and robots.

However, the business is constrained by factors including high upfront expenditures and the intricate data handling needed for HTS systems. The lack of qualified personnel to run cutting-edge screening equipment is another barrier to market expansion. The increasing use of machine learning and artificial intelligence to streamline data analysis and screening procedures presents opportunities. Collaboration between academic institutions and pharmaceutical businesses may additionally encourage innovation in HTS technology. Trends include creating assays for complicated biological systems and high-content screening techniques, as well as integrating miniaturized and lab-on-a-chip technologies to increase screening efficiency.

Facts & Figures

• The Council of Scientific and Industrial Research (CSIR) of India spent US$ 6.73 million on research and development (R&D) related to drug discovery.
• The Medical Research Agency (Poland) announced financing of US$ 73.3 million (PLN 300 million) to support the development of mRNA-based vaccines in Poland.
• A new national medicinal chemistry setup called MedChem Australia was founded with US$ 9.75 million from the Medical Research Future Fund (MRFF) of the Commonwealth Government of Australia. The goal of the funding is to identify early-stage therapeutic candidates.

Key Players

The high throughput screening market share is inclusive of several companies such as Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Revvity Inc. (U.S.), Tecan Group Ltd. (Switzerland), Axxam S.p.A. (Italy), Charles River Laboratories International, Inc. (U.S.), Hamilton Company (U.S.), Promega Corporation (U.S.), and Aurora Biomed Inc. (Canada).

Key Developments

• In April 2024, The HTS services offered by Metrion Biosciences Limited and Enamine Ltd were expanded to include Enamine's compound libraries. Through the collaboration, Metrion will be able to enhance research and discover new drugs.
• In February 2023, The EnVison Nexus Multimode plate reader was launched by PerkinElmer to further research and development efforts.

High Throughput Screening Market Segmentation

By Product & Service: There is a major section in the high-throughput screening (HTS) market identified as reagents and assay kits. Reagents are needed for assessing a wide range of biochemical interactions in drug development and research procedures; therefore, the reason of assays are becoming more and more prevalent. Reliable reagents and assay kits that yield precise and repeatable findings are increasingly needed as the market for economical and effective screening techniques expands. The demand for these goods is also fueled by the growth of biopharmaceutical and personalized medicine since these products are necessary for high-throughput assays utilized in pharmaceutical and biotechnology firms' huge compound libraries' screening. 

By Technology: Particularly 2D and 3D cell cultures, cell-based assays rule the high-throughput screening (HTS) market. Because these tests closely resemble in vivo circumstances, they are commonly employed in toxicology and drug development research because they yield more physiologically relevant data. 3D cell cultures are becoming more and more popular because they can more closely mimic the architecture of human tissue, which can produce more accurate predictions. Furthermore, there is a greater need for cell-based assays due to the growing emphasis on personalized medicine and disease-specific medication development. Their capacity to adjust and be flexible in high-throughput settings makes them essential for effectively and consistently screening large chemical libraries.

By Application: The most common use in the high-throughput screening (HTS) market is drug discovery programs. This is due to the biotechnology and pharmaceutical sectors experiencing an increase in demand for quick and effective screening techniques to find possible treatment options. HTS speeds up the first phases of drug development by enabling the simultaneous screening of thousands of molecules. Pharmaceutical companies heavily rely on HTS to expedite the drug discovery process, lower costs, and increase the success rate of identifying viable therapeutic compounds, making it essential to modern drug development given the rising prevalence of chronic diseases and the push for personalized medicine.

By End User: The main end users in the high-throughput screening (HTS) market are pharmaceutical and biopharmaceutical companies. They mostly rely on HTS to accelerate drug discovery by effectively and affordably screening sizable chemical libraries for possible therapeutic candidates. Their extensive consumption of HTS is motivated by the need to swiftly invent and create novel medications in response to growing health issues, including chronic illnesses and customized medicine. In addition, in the highly competitive pharmaceutical industry, it is imperative to identify promising compounds quickly. For this purpose, high-throughput screening (HTS) is an essential tool for organizations looking to speed up R&D, save expenses, and promote drug research.